One of the few manufacturers in the world that meets the high-quality research standards in the U.S. and Europe for medicinal cannabinoid (CBD) is collaborating with University of Miami Miller School of Medicine researchers, providing the company’s product for groundbreaking studies.
As the COVID-19 pandemic unfolds, inaccurate medical information has flooded social media and other channels. One potentially lethal example is that patients who take renin-angiotensin system (RAS) blockers, particularly angiotensin II type 1 receptor blockers (ARBs), may be more susceptible to the virus.
Biomedical researchers at the University of Miami Miller School of Medicine are developing a COVID-19 point-of-care diagnostic test in collaboration with biopharmaceutical company Heat Biologics, Inc.
Natalia Parra was nervous about where she would be placed for an obstetrics-gynecology residency after earning her medical degree at the University of Miami Miller School of Medicine. “This is the next step in my career, and all my studies have led to this point,” she said, before learning she would be going to New York Presbyterian Hospital-Columbia University Medical Center in New York.
Traditionally, many surgeons performing a segmentectomy to remove a limited portion of the lung affected by cancer will switch to a lobectomy – removal of an entire lobe of the lung – during surgery if nearby lymph nodes also test positive for cancer.